<?xml version="1.0" encoding="UTF-8"?>
<p>Collectively, ADE is now considered to be the underlying mechanism for enhanced risk of DHF/DSS in secondary dengue virus infection, and it highlights the necessity of avoiding the induction of inadequate immune response toward any serotypes during vaccine development. Despite the impact of prior cross-serocomplex immunity for subsequent ZIKV or DENV infections are clinically unknown, candidate vaccines that provide protection and avoid ADE should be prioritized for development.</p>
